Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 288Gynecologic 18CNS 9Sarcoma 7Genitourinary 7Gastrointestinal 7Endocrine 3Tumor-Agnostic 2Thoracic 2Lymphoid 2Head & Neck 2Dermatologic 2Other solid neoplasm 1Other 1NET 1

Conditions

Uveal Melanoma 1Melanoma 1

Interventions

pembrolizumab 326Nivolumab 289Ipilimumab 260Cyclophosphamide 193aldesleukin 145Interleukin-2 109fludarabine phosphate 106Temozolomide 83Dacarbazine 81fludarabine 80Radiotherapy 74trametinib 73Vemurafenib 69dabrafenib 66Biopsy 65sargramostim 50Bevacizumab 50Radiosurgery 49Paclitaxel 49Peripheral Blood Stem Cell Transplantation 48Carboplatin 48Magnetic Resonance Spectroscopy 47Imiquimod 47Aminolevulinic Acid 47binimetinib 45Cisplatin 45CTLA-4 Antigen 43cemiplimab 42atezolizumab 41Specimen Handling 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Tamoxifen × Dermatologic × Clear all
NCT00489944 2014-01-10

Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma

National Cancer Institute (NCI)

Phase 2 Unknown
50 enrolled
Dermatologic

Uveal Melanoma

NCT00492505 2014-01-10

Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma

National Cancer Institute (NCI)

Phase 2 Unknown
200 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡